53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19–9 in pancreatic adenocarcinoma

BMC Cancer

Natalie L Ausborn⁴  Tong Wang⁴  Sabrina C Wentz⁵  Mary Kay Washington⁵  Nipun B Merchant³  Zhiguo Zhao¹  Yu Shyr¹  Anuradha Bapsi Chakravarthy⁴  Fen Xia² 

[1] Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA

[2] Department of Radiation Oncology, The Ohio State University College of Medicine, Starling Loving, 300 W 10th Avenue, Columbus, OH, 43210, USA

[3] Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA

[4] Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA

[5] Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA

关键词: Repair;    DNA damage;    Pancreatic cancer;    53BP1;    BRCA1 protein;   

Others  :  1079835
DOI  :  10.1186/1471-2407-13-155

 received in 2012-09-25, accepted in 2013-03-08,  发布年份 2013

【 摘 要 】

Background

53BP1 binds to the tumor suppressor p53 and has a key role in DNA damage response and repair. Low 53BP1 expression has been associated with decreased survival in breast cancer and has been shown to interact with several prognostic factors in non-small cell lung cancer. The role of 53BP1 in pancreatic ductal adenocarcinoma (PDAC) has yet to be determined. We aimed to investigate whether 53BP1 levels interact with established prognostic factors in PDAC.

Methods

106 patients for whom there was tissue available at time of surgical resection for PDAC were included. A tissue microarray was constructed using surgical specimens, stained with antibodies to 53BP1, and scored for expression intensity. Univariate and multivariate statistical analyses were performed to investigate the association between 53BP1 and patient survival with known prognostic factors for survival.

Results

The association of 53BP1 with several established prognostic factors was examined, including stage, tumor grade, surgical margin, peripancreatic extension, lymph node ratio (LNR), and CA 19–9. We found that 53BP1 modified the effects of known prognostic variables including LNR and CA 19–9 on survival outcomes. When 53BP1 intensity was low, increased LNR was associated with decreased OS (HR 4.84, 95% CI (2.26, 10.37), p<0.001) and high CA19-9 was associated with decreased OS (HR 1.72, 95% CI (1.18, 2.51), p=0.005). When 53BP1 intensity was high, LNR and CA19-9 were no longer associated with OS (p=0.958 and p=0.606, respectively).

Conclusions

In this study, 53BP1, a key player in DNA damage response and repair, was found to modify the prognostic value of two established prognostic factors, LNR and CA 19–9, suggesting 53BP1 may alter tumor behavior and ultimately impact how we interpret the value of other prognostic factors.

【 授权许可】

   
2013 Ausborn et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jermal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Yeo CJ, Abrams RA, Grochow LB: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997, 225:621-633.
• [3]Sohn TA, Yeo CJ, Cameron JL: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000, 4:567-579.
• [4]Cameron JL, Pitt HA, Yeo CJ: One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993, 217:430-438.
• [5]Balcom JH, Rattner DW, Warshaw AL: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001, 136:391-398.
• [6]Birkmeyer JD, Finlayson SR, Tosteson AN: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999, 125:250-256.
• [7]Hsu CC, Herman JM, Corsini MM: Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010, 17:981-990.
• [8]Corsini MM, Miller RC, Haddock MG: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol 2008, 26:3511-3516.
• [9]Klinkenbijl JH, Jeekel J, Sahmoud T: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:776-782.
• [10]Neoptolemos JP, Dunn JA, Stocken DD: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
• [11]Neoptolemos JP, Stocken DD, Friess H: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350:1200-1210.
• [12]Wang B, Matsuoka S, Carpenter PB, Elledge S: 53BP1, a mediator of the DNA damage checkpoint. Science 2002, 298:1435-1438.
• [13]Moynahan ME, Jasin M: Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010, 11:196-207.
• [14]Xie A, Hartlerod A, Stucki M: Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell 2007, 28:1045-1057.
• [15]Banerjee S, Kaye S: PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011, 13:442-449.
• [16]Comen EA, Robson M: Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer K 2010, 16:48-52.
• [17]Bunting SF, Callen E, Wong N: 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
• [18]Bouwman P, Aly A, Escandell JM: 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010, 17:688-695.
• [19]Edge SB, Byrd DR, Compton CC: AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010.
• [20]Westra WH, Hruban RH, Phelps TH, Isacson C: Pancreas. 2nd edition. New York: Springer; 2003:88-92. [Surgical Pathology Dissection: An Illustrated Guide]
• [21]College of American Pathologists Cancer: Protocol for the examination of specimens from patients with carcinoma of the exocrine pancreas. [http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/PancreasExo_11protocol.pdf webcite]
• [22]Karimi-Busheri F, Rasouli-Nia A, Mackey JR: Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010, 12:R31. BioMed Central Full Text
• [23]Grotsky DA, Gonzalez-Suarez I, Novell A: BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells. J Cell Biol 2013, 200:187-202. Reference 23 in revised manuscript
• [24]Neboori HJR, Haffty BG, Wu H: Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:c677-c683.
• [25]R Development Core Team: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
• [26]Prados MD, Chang SM, Butowski N: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27:579-584.
• [27]Smith RA, Bosonnet L, Ghaneh P: Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008, 25:226-232.
• [28]Kondo N, Murakami Y, Uemura K: Prognostic impact of perioperative serum CA 19–9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010, 17:2321-2329.
• [29]Ikeda M, Okada S, Tokuuye K: Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001, 91:490-495.
• [30]Micke O, Bruns F, Kurowski R: Predictive value of carbohydrate antigen 19–9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:90-97.
• [31]Saad ED, Machado MC, Wajsbrot D: Pretreatment CA 19–9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002, 32:35-41.
• [32]Berger AC, Sigurdson ER, LeVoyer T: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005, 23:8706-8712.
• [33]Inoue K, Nakane Y, Iiyama H: The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002, 9:27-34.
• [34]Negi SS, Singh A, Chaudhary A: Lymph nodal involvement as prognostic factor in gallbladder cancer: location, count or ratio? J Gastrointest Surg 2011, 15:1017-1025.
• [35]Nitti D, Marchet A, Olivieri M: Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003, 10:1077-1085.
• [36]Wijnhoven BP, Tran KT, Esterman A: An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 2007, 245:717-725.
• [37]Berger AC, Watson JC, Ross EA, Hoffman JP: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004, 70:235-240.
• [38]Pawlik TM, Gleisner AL, Cameron JL: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007, 141:610-618.
• [39]Riediger H, Keck T, Wellner U: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009, 13:1337-1344.
• [40]House MG, Gonen M, Jarnagin WR: Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007, 11:1549-1555.
• [41]Willett CG, Daly WJ, Warshaw AL: CA 19–9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996, 172:350-352.
• [42]Abrams RA, Grochow LB, Chakravarthy A: Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999, 44:1039-1046.
• [43]Lundin J, Roberts PJ, Kuusela P, Haglund C: The prognostic value of preoperative serum levels of CA 19–9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69:515-519.
• [44]Lai TC, Chow KC, Lin TY: Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas. Oncol Rep 2010, 24:321-328.